Ublituximab-xiiy (Briumvi)

Briumvi (ublituximab-xiiy) is a CD20-directed monoclonal antibody indicated for the treatment of adults with relapsing forms of multiple sclerosis (MS), including: Clinically isolated syndrome (CIS), Relapsing-remitting MS (RRMS), Active secondary progressive MS (SPMS). It works by binding to CD20 on the surface of B lymphocytes, inducing antibody-dependent and complement-mediated cell lysis, thereby reducing relapse frequency and delaying disability progression. <a id="